提到HR+/HER2-早期乳腺癌，很多人觉得“治愈率高”就可以放松警惕。但真实情况是，不少患者在化疗、放疗、内分泌治疗等常规综合治疗后仍可能面临复发风险，尤其是一些之前被忽视的高危人群，复发概率甚至是普通患者的2-3倍，这一风险还可能持续长达20年[ ...

HR+/HER2 - 乳腺癌的治愈潜力，源于其独特的生物学特征。这类肿瘤细胞表面存在激素受体，生长依赖雌激素或孕激素信号，内分泌治疗可精准阻断这一 “营养通道”，抑制肿瘤增殖 ...

2026 年 1 月 22 日，中国国家药品监督管理局（NMPA）正式批准德曲妥珠单抗（T-DXd）单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性 HER2 ...

胃癌及胃食管结合部腺癌（GC/GEJA）是我国疾病负担最为沉重的肿瘤之一。HER2 阳性胃癌因其生物学特征明确、可靶向性强，始终是临床治疗策略演进的重要切入点。过去十余年间，随着抗 HER2 单克隆抗体、抗体偶联药物（ADC）以及免疫治疗等多种新型治疗手段相继进入临床，HER2 ...

Most types of breast cancer produce similar symptoms and are discovered the same way—finding a strange new lump during a self-exam, or a healthcare provider spotting something suspicious during a ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

Iambic Therapeutics has advanced its first pipeline candidate into the clinic, an AI-designed treatment for human epidermal growth factor receptor 2 (HER2)-driven cancers that moved from discovery to ...

Systemic treatment for human epidermal growth factor receptor 2-positive breast cancer includes a range of targeted therapies designed to inhibit HER2 signaling, improve tumor response and limit ...